Advancing Patient Care
Together we can generate real-world clinical evidence that matters
Explore Natera sponsored clinical trials in Oncology
BESPOKE Pan Cancer
Goal:
- Study aims to enroll to 5,000 participants across all cancer types and collect robust clinical data longitudinally (5 years)
- Evaluate correlation between ctDNA and outcomes and provider utilization habits of the assay (i.e. setting, cadence)
Contact: bespokepcstudy@natera.com
SCORE
Goal:
- Study aims to enroll participants for initial cancer indications with collections of both blood and tissue in a ctDNA naive setting to evaluate the association between ctDNA testing and outcomes
- To evaluate agreement between Latitude (tissue-free MRD) and Signatera (tissue-informed MRD) results
Contact: scorestudy@natera.com
SIGNAL CDK
Goal:
- Evaluate non-inferiority of ctDNA-guided CDK4/6 inhibitor initiation vs historical NATALEE data for invasive disease-free survival (DFS)
- Assess disease recurrence free survival (DRFS), overall survival (OS), ctDNA detection rates and timing, clearance rates after CDK4/6 inhibitor initiation, and quality of life outcomes
Contact: SignalCDKstudy@natera.com